Puration, Kaly Confirm M&A Deal, Say Research Underway On CBD, Coronavirus Symptoms
04 Marzo 2020 - 3:11PM
InvestorsHub NewsWire
Puration, Kaly Confirm M&A
Deal, Say Research Underway On CBD, Coronavirus Symptoms
March 4, 2020 -- InvestorsHub NewsWire -- via Jose
Rodrigo , Benzinga Staff Writer
March 03, 2020
Puration Inc PURA and Kali-Extracts KALY said
Monday that a planned acquisition by Pura of Kaly's CBD confections operations is underway.
Kaly is focusing its business on cannabis extract
biopharmaceuticals, and its leading research has been on the
treatment of respiratory conditions, the companies said.
Kaly has filed a new patent application on its CBD formulation
for the symptoms of COPD and similar respiratory conditions, the
companies said. The company has also filed for a trademark on the
name RespRx as a brand of CBD for COPD symptoms and other
conditions that cause respiratory inflammation.
The company said it is evaluating its proprietary CBD extract
formulation as a treatment for symptoms of coronavirus.
See other recent BENZINGA articles on cannabis sector compaines
including James E. Wagner Cultivation
Corporation (OTC:JWCAF), and Tilray, Inc.
(TLRY).
SOURCE: Jose Rodrigo, Benzinga Staff Writer
Grafico Azioni James E Wagner Cultivation (CE) (USOTC:JWCAF)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni James E Wagner Cultivation (CE) (USOTC:JWCAF)
Storico
Da Dic 2023 a Dic 2024
Notizie in Tempo Reale relative a James E Wagner Cultivation Corporation (CE) (OTCMarkets): 0 articoli recenti
Più James E Wagner Cultivation Corporation (QX) Articoli Notizie